euro adhoc: november AG
Joint Ventures/Cooperation/Collaboration
november AG
names GBN Systems GmbH the cooperation partner for subsidiary device development
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement.
22.09.2005
Changes to the contract with Siemens free the way for a new partner in the analyzer development of directif GmbH
Erlangen, Germany 22 September 2005 The Erlangen based bio- and nanotechnology holding company, november AG (ISIN DE0006762909), will immediately continue the development of its analyzer for the complete system of rapid and laboratory independent nucleic acid diagnostics, the primary project of its subsidiary directif GmbH, together with GBN Systems GmbH. This is facilitated through contractual changes in cooperation with Siemens AG, the previous strategic partner in the development of the analyzer.
The cooperation with GBN Systems, who develops and produces customer specific electro-technological equipment and fine technological structural components, includes the further development of the analysis device, its transfer into production readiness and manufacture. As both contractual partners are aiming at a long term partnership, the new cooperation is supported by provenion GmbH, a longstanding contractual partner of GBN Systems, which specializes in the development of innovative technologies.
Through the cooperation, the end price for the analysis device will be significantly reduced.
The collaboration with GBN Systems supersedes the previous cooperation with Siemens AG, whose right of exclusivity was rescinded through changes to the previous partnership contract.
- End of the ad-hoc-release -
Explanations:
The complete system, which is currently being developed by directif GmbH, will identify infectious agents and changes in human genetic material reliably and cost-effectively. The novel, fully automatic mini laboratory, has room on any desk and serves the rapid analysis of nucleic acid contained, for example, in blood or urine samples. It is comprised of the controllable analyzer and a newly developed microfluid disposable cartridge, which is ready for series production in an injection moulding process by Wilden AG, another strategic partner of november AG.
"GBN has already successfully developed and manufactured electromechanical devices in the past for the life sciences market, e.g. the electronic central unit for the steering of the medical operation system from BrainLAB AG. We therefore anticipate a consequential further development of our analyzer with this partnership," says novembers CEO, Dr. Wolf M. Bertling. "We have already been producing equipment for 17 years according to the individual requirements and full satisfaction of our customers. We are therefore very pleased to have gained november AG as a new customer and partner," adds Siegfried Foerg, Managing Director of GBN Systems GmbH.
november AG, Erlangen, Germany, is listed at the Prime Standard of the Frankfurt Stock Exchange, ISIN DE0006762909, symbol (NBX). November AG is a Bio- and Nanotechnology holding company that develops and invests in new technologies. The group comprises among others the subsidiaries identif GmbH (brand protection & product safety), directif GmbH (Medtech, diagnostics of nucleic acids) and PEQLAB Biotechnologie GmbH (the link between research in molecular biology and the market).
GBN Systems GmbH is a system supplier and OEM manufacturer for all areas of machine construction industry and apparatus manufacturing. The company produces, develops and constructs electro-technical, electronic and micro mechanical components, assemblies and complete units for semiconductor production machines, for production machines for optical data carriers, for packaging technology, for many areas of medical technology as well as for logistics systems and warning systems and other branches. GBN Systems is manufacturer of power supplies for different machines, devices. All its products are developed, designed and produced exactly to customer specifications.
provenion GmbH is a research and development team engineering new ideas and translating them into practice. provenion supplies evidence of competence in special machinery, measuring technique and combustion engine development for many years. Designing and electronics engineers, precision mechanics and test engineers work together under one umbrella to provide successful solutions from one source - from clean sheet to entire system. Awareness of quality, customer orientation and team spirit are the main features of operating mode and make sure to handle orders professionally as well as to meet budgets and deadlines. The quality management system of provenion is certified according to DIN EN ISO 9001:2000.
end of announcement euro adhoc 22.09.2005 17:43:50
Further inquiry note:
Andrea Steuer
Manager Investor Relations/Public Relations
Tel.: +49(0)9131-75088-868
Fax: +49 (0)9131-75088-999
E-Mail: steuer@november.de
Branche: Biotechnology
ISIN: DE0006762909
WKN: 676290
Index: CDAX, Technologie All Share, Prime All Share, Prime Standard
Börsen: Frankfurter Wertpapierbörse / regulated dealing
Berliner Wertpapierbörse / free trade
Baden-Württembergische Wertpapierbörse / free trade
Börse Düsseldorf / free trade
Niedersächsische Börse zu Hannover / free trade
Bayerische Börse / free trade
Bremer Wertpapierbörse (BWB) / free trade